Frequently Asked Questions about Seres Therapeutics, Inc. (MCRB)

Name: Seres Therapeutics, Inc. (MCRB) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Seres Therapeutics, Inc. (MCRB) do?

Accepted Answer

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that ...

Question 2

Is Seres Therapeutics, Inc. (MCRB) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of MCRB reveals an Altman Z-Score of -9.01 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if MCRB fits their risk profile.

Question 3

What is the current P/E ratio for MCRB?

Accepted Answer

As of the latest trading session, Seres Therapeutics, Inc. (MCRB) has a trailing P/E ratio of 12.94.

Question 4

Who is the CEO of Seres Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Seres Therapeutics, Inc. is Richard N. Kender.

Question 5

What was MCRB's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Seres Therapeutics, Inc. reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.14B (2021) respectively.

Question 6

Does MCRB pay a dividend?

Accepted Answer

Seres Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does MCRB have?

Accepted Answer

In its latest reporting period, Seres Therapeutics, Inc. generated $0.00B in Free Cash Flow against a total debt load of $0.08B.

Question 8

What is the Price-to-Book (P/B) ratio of Seres Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Seres Therapeutics, Inc. (MCRB) is currently 1.67.

Question 9

What is the Price-to-Sales (P/S) ratio of MCRB?

Accepted Answer

Based on trailing twelve-month data, Seres Therapeutics, Inc. (MCRB) trades at a Price-to-Sales (P/S) ratio of 101.09.

Question 10

What is Seres Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Seres Therapeutics, Inc. (MCRB) has a Return on Equity (ROE) of 13.30%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	789K	-3.3M	-94M	5.7M	0.64
2024-12	0	-3.5M	-121.3M	136K	-18.86
2023-12	0	0	-195.1M	-113.7M	-17.77
2022-12	0	0	-179.9M	-250.2M	-46.29
2021-12	144.9M	144.9M	-64.5M	-65.6M	-14.30